ABRAMS' dKCLINICAL dKDRUG dKTHERAPY: dKRATIONALES dKFOR dKNURSING dKPRACTICE
,ABRAMS' dKCLINICAL dKDRUG dKTHERAPY: dKRATIONALES dKFOR dKNURSING dKPRACTICE
,ABRAMS' dKCLINICAL dKDRUG dKTHERAPY: dKRATIONALES dKFOR dKNURSING dKPRACTICE
, ABRAMS' dKCLINICAL dKDRUG dKTHERAPY: dKRATIONALES dKFOR dKNURSING dKPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
dK dK dK dK dK dK dK dK
1. A dKwoman dKdiagnosed dKwith dKobsessive–compulsive dKdisorder dKhas dKbeen
dKprescribed dKoraldparoxetine dKhydrochloride. dKWhat dKis dKthe dKexpected dKeffect dKfor
K
dKthis dKprescription?
A. Curative dKeffect dKon dKsymptoms
B. Systemic dKeffect dKon dKsymptoms
C. Local dKeffect dKon dKsymptoms
D. Parenteral dKeffect dKon dKsymptoms
ANS: d K B
Rationale: dKDrugs dKthat dKproduce dKsystemic dKeffects dKare dKtaken dKinto dKthe dKbody, dKcirculated
dKthrough dKthe dKbloodstream dKto dKtheir dKsites dKof dKaction dKin dKvarious dKbody dKtissues, dKand
dKeventually dKeliminated dKfrom dKthe dKbody. dKCurative dKagents dKare dKgiven dKto dKcure dKa
dKdisease dKprocess. dKIn dKthis dKcase, dKparoxetine dKhydrochloride dKwill dKcontrol dKthe dKsymptoms
dKbut dKnot dKcure dKthe dKdisorder. dKDrugs dKwith dKlocal dKeffects,dK
such dKas dKsunscreen dKand dKlocal
dKanesthetics, dKact dKmainly dKat dKthe dKsite dKof dKapplication. dKParoxetine dKhydrochloride dKis dKnot
dKadministered dKparenterally. dKParenteral dKagents dKare dKadministered dKsubcutaneously,
dKintramuscularly, dKor dKintravenously.
PTS: 1 REF: p. dK3, dKIntroduction OBJ: 1
NAT: d K Client dKNeeds: dKPhysiological dKIntegrity: dKPharmacological dKand dKParenteral
dKTherapiesd
KTOP: Chapter: dK1: dKThe dKFoundation dKof dKPharmacology: dKQuality dKand
dKSafety
KEY: d K Integrated dKProcess: dKNursing dKProcess
BLM: d K Cognitive dKLevel: dKUnderstand NOT: d K Multiple dKChoice
2. A dKclient dKhas dKbeen dKprescribed dKan dKantibiotic. dKThis dKmedication dKis dKa dKnaturally dKoccurring
substance dKthat dKhas dKbeen dKcheG
mR icA
alDlyEm
SoBdOifOieSd.TWhaOtdKM
.C is dKanother dKname dKfor dKthis
dKtype dKof dKmedication?
A. Synthetic dKdrug
B. Semisynthetic dKdrug
C. Biotechnology dKdrug
D. Prototype dKdrug
ANS: d K B
Rationale: dKSemisynthetic dKdrugs dK(e.g., dKmany dKantibiotics) dKare dKnaturally dKoccurring
dKsubstances dKthat dKhave dKbeen dKchemically dKmodified. dKSynthetic dKdrugs dKare dKmore
dKstandardized dKin dKtheir dKchemicaldK characteristics, dKmore dKconsistent dKin dKtheir dKeffects, dKand
dKless dKlikely dKto dKproduce dKallergic dKreactions. dKBiotechnology dKdrugs dKinvolve
dKmanipulating dKDNA dKand dKRNA dKand dKrecombining dKgenes dKinto dKhybrid dKmolecules dKthat
dKcan dKbe dKinserted dKinto dKliving dKorganisms. dKPrototype dKdrugs dKare dKthe dKfirst dKdrug dKof dKa
dKparticular dKgroup dKto dKbe dKdeveloped.
PTS: 1 REF: p. dK3, dKDrug dKSources OBJ: 1
NAT: d K Client dKNeeds: dKPhysiological dKIntegrity: dKPharmacological dKand dKParenteral
dKTherapiesd
KTOP: Chapter: dK1: dKThe dKFoundation dKof dKPharmacology: dKQuality dKand
dKSafety
KEY: d K Integrated dKProcess: dKNursing dKProcess
BLM: d K Cognitive dKLevel: dKUnderstand NOT: d K Multiple dKChoice
3. Which dKclassification dKapplies dKto dKmorphine?
A. Central dKnervous dKsystem dKdepressant
ABRAMS' dKCLINICAL dKDRUG dKTHERAPY: dKRATIONALES dKFOR dKNURSING dKPRACTICE
,ABRAMS' dKCLINICAL dKDRUG dKTHERAPY: dKRATIONALES dKFOR dKNURSING dKPRACTICE
,ABRAMS' dKCLINICAL dKDRUG dKTHERAPY: dKRATIONALES dKFOR dKNURSING dKPRACTICE
, ABRAMS' dKCLINICAL dKDRUG dKTHERAPY: dKRATIONALES dKFOR dKNURSING dKPRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
dK dK dK dK dK dK dK dK
1. A dKwoman dKdiagnosed dKwith dKobsessive–compulsive dKdisorder dKhas dKbeen
dKprescribed dKoraldparoxetine dKhydrochloride. dKWhat dKis dKthe dKexpected dKeffect dKfor
K
dKthis dKprescription?
A. Curative dKeffect dKon dKsymptoms
B. Systemic dKeffect dKon dKsymptoms
C. Local dKeffect dKon dKsymptoms
D. Parenteral dKeffect dKon dKsymptoms
ANS: d K B
Rationale: dKDrugs dKthat dKproduce dKsystemic dKeffects dKare dKtaken dKinto dKthe dKbody, dKcirculated
dKthrough dKthe dKbloodstream dKto dKtheir dKsites dKof dKaction dKin dKvarious dKbody dKtissues, dKand
dKeventually dKeliminated dKfrom dKthe dKbody. dKCurative dKagents dKare dKgiven dKto dKcure dKa
dKdisease dKprocess. dKIn dKthis dKcase, dKparoxetine dKhydrochloride dKwill dKcontrol dKthe dKsymptoms
dKbut dKnot dKcure dKthe dKdisorder. dKDrugs dKwith dKlocal dKeffects,dK
such dKas dKsunscreen dKand dKlocal
dKanesthetics, dKact dKmainly dKat dKthe dKsite dKof dKapplication. dKParoxetine dKhydrochloride dKis dKnot
dKadministered dKparenterally. dKParenteral dKagents dKare dKadministered dKsubcutaneously,
dKintramuscularly, dKor dKintravenously.
PTS: 1 REF: p. dK3, dKIntroduction OBJ: 1
NAT: d K Client dKNeeds: dKPhysiological dKIntegrity: dKPharmacological dKand dKParenteral
dKTherapiesd
KTOP: Chapter: dK1: dKThe dKFoundation dKof dKPharmacology: dKQuality dKand
dKSafety
KEY: d K Integrated dKProcess: dKNursing dKProcess
BLM: d K Cognitive dKLevel: dKUnderstand NOT: d K Multiple dKChoice
2. A dKclient dKhas dKbeen dKprescribed dKan dKantibiotic. dKThis dKmedication dKis dKa dKnaturally dKoccurring
substance dKthat dKhas dKbeen dKcheG
mR icA
alDlyEm
SoBdOifOieSd.TWhaOtdKM
.C is dKanother dKname dKfor dKthis
dKtype dKof dKmedication?
A. Synthetic dKdrug
B. Semisynthetic dKdrug
C. Biotechnology dKdrug
D. Prototype dKdrug
ANS: d K B
Rationale: dKSemisynthetic dKdrugs dK(e.g., dKmany dKantibiotics) dKare dKnaturally dKoccurring
dKsubstances dKthat dKhave dKbeen dKchemically dKmodified. dKSynthetic dKdrugs dKare dKmore
dKstandardized dKin dKtheir dKchemicaldK characteristics, dKmore dKconsistent dKin dKtheir dKeffects, dKand
dKless dKlikely dKto dKproduce dKallergic dKreactions. dKBiotechnology dKdrugs dKinvolve
dKmanipulating dKDNA dKand dKRNA dKand dKrecombining dKgenes dKinto dKhybrid dKmolecules dKthat
dKcan dKbe dKinserted dKinto dKliving dKorganisms. dKPrototype dKdrugs dKare dKthe dKfirst dKdrug dKof dKa
dKparticular dKgroup dKto dKbe dKdeveloped.
PTS: 1 REF: p. dK3, dKDrug dKSources OBJ: 1
NAT: d K Client dKNeeds: dKPhysiological dKIntegrity: dKPharmacological dKand dKParenteral
dKTherapiesd
KTOP: Chapter: dK1: dKThe dKFoundation dKof dKPharmacology: dKQuality dKand
dKSafety
KEY: d K Integrated dKProcess: dKNursing dKProcess
BLM: d K Cognitive dKLevel: dKUnderstand NOT: d K Multiple dKChoice
3. Which dKclassification dKapplies dKto dKmorphine?
A. Central dKnervous dKsystem dKdepressant
ABRAMS' dKCLINICAL dKDRUG dKTHERAPY: dKRATIONALES dKFOR dKNURSING dKPRACTICE
